Pomerantz LLP filed a securities class action Tuesday in California Northern District Court against AcelRx Pharmaceuticals, its CEO and its CFO. The complaint accuses the defendants of making misleading claims regarding the efficacy of AcelRx's Dsuvia pain medication, and potential risks in taking it. Counsel have not yet appeared for the defendants. The case is 3:21-cv-04353, Sneed Jr. v. AcelRx Pharmaceuticals, Inc. et al.
Biotech & Pharmaceuticals
June 08, 2021, 12:34 PM